Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 01/09/2015
Chairman 71 15/04/2021
Director/Board Member 59 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
-0.68%-0.68%-1.63%+12.86% 48.22B
+6.03%+5.22%+420.33%+519.87% 38.79B
-2.21%-6.07%+24.87%+5.20% 38.41B
+2.94%-2.25%+6.15%+59.69% 34.88B
+1.98%+4.74%+12.19%+41.37% 29.19B
+0.47%-3.87% - - 16.05B
+0.31%+0.72%+32.99%+122.25% 16B
+1.59%+0.44%+3.43%+16.80% 13.53B
-0.98%-12.98%-4.82%-38.09% 12.22B
Average +1.53%+0.01%+61.69%+92.49% 27.48B
Weighted average by Cap. +1.21%+1.55%+78.99%+112.40%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock